Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
High-field imaging of neurodegenerative diseases.
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
UVB light attenuates the systemic immune response in CNS autoimmunity.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
Acute disseminated encephalomyelitis--a prospective study of clinical profile and in-hospital outcome predictors.
The ketogenic diet as a treatment paradigm for diverse neurological disorders.
Magnetic resonance imaging in multiple sclerosis - patients' experiences, information interests and responses to an education programme.
Chronic inflammatory demyelinating polyneuropathy following malignant melanoma.
Tysabri
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
Benign Multiple Sclerosis: Does it exist?
Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis.
A telerehabilitation program by virtual reality-video games improves balance and postural control in multiple sclerosis patients.
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis.
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
The cost burden of multiple sclerosis in the United States: a systematic review of the literature.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

Pages